Menu Search
Equities

Eurobio Scientific SA

ALERS:PAR

Eurobio Scientific SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)24.90
  • Today's Change-0.05 / -0.20%
  • Shares traded20.68k
  • 1 Year change+63.17%
  • Beta-0.7455
Data delayed at least 15 minutes, as of Sep 20 2024 10:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Eurobio Scientific SA's revenues fell -14.81% from 152.61m to 130.00m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 24.94m to 4.84m, a -80.61% decrease.
Gross margin47.11%
Net profit margin3.72%
Operating margin6.69%
Return on assets1.49%
Return on equity2.78%
Return on investment1.80%
More ▼

Cash flow in EURView more

In 2023, Eurobio Scientific SA did not generate a significant amount of cash. However, the company earned 26.77m from its operations for a Cash Flow Margin of 20.59%. In addition the company used 318.00k on investing activities and also paid 23.50m in financing cash flows.
Cash flow per share1.60
Price/Cash flow per share14.22
Book value per share16.02
Tangible book value per share2.00
More ▼

Balance sheet in EURView more

Eurobio Scientific SA has a Debt to Total Capital ratio of 36.66%, a lower figure than the previous year's 57.33%.
Current ratio2.72
Quick ratio2.32
Total debt/total equity0.5788
Total debt/total capital0.3666
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -82.27%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-82.18
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.